EUVIMEDEUVIMED entdecken
Crossref

Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae

Mei Zheng, Fu-Hao Li, Juan Liu, Wen-Jie Li, Ruo-Xi Yin, Da-Tong Cai, Diego O Andrey, Si-Lin Zheng, Ana C Gales iD, Wan-Jiang Zhang iD, Jian Sun iD, Xiao-Ping Liao und 1 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Mei Zheng und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China. Hauptthemen laut MEDLINE: Ceftazidime, Klebsiella pneumoniae, Drug Combinations, Azabicyclo Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Swiss National Science Foundation, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The emergence and expansion of carbapenem-resistant Klebsiella pneumoniae infections is a concern due to the lack of ‘first-line’ antibiotic treatment options. The ceftazidime/avibactam is an important clinical treatment for carbapenem-resistant K. pneumoniae infections but there is an increasing number of cases of treatment failure and drug resistance. Therefore, a potential solution is combination therapies that result in synergistic activity against K. pneumoniae carbapenemase: producing K. pneumoniae (KPC-Kp) isolates and preventing the emergence of KPC mutants resistant to ceftazidime/avibactam are needed in lieu of novel antibiotics.

Methods

To evaluate their synergistic activity, antibiotic combinations were tested against 26 KPC-Kp strains. Antibiotic resistance profiles, molecular characteristics and virulence genes were investigated by susceptibility testing and whole-genome sequencing. Antibiotic synergy was evaluated by in vitro chequerboard experiments, time-killing curves and dose–response assays. The mouse thigh model was used to confirm antibiotic combination activities in vivo. Additionally, antibiotic combinations were evaluated for their ability to prevent the emergence of ceftazidime/avibactam resistant mutations of blaKPC.

Results

The combination of ceftazidime/avibactam plus meropenem showed remarkable synergistic activity against 26 strains and restored susceptibility to both the partnering antibiotics. The significant therapeutic effect of ceftazidime/avibactam combined with meropenem was also confirmed in the mouse model and bacterial loads in the thigh muscle of the combination groups were significantly reduced. Furthermore, ceftazidime/avibactam plus meropenem showed significant activity in preventing the occurrence of resistance mutations.

Conclusions

Our results indicated that the combination of ceftazidime/avibactam plus meropenem offers viable therapeutic alternatives in treating serious infections due to KPC-Kp.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeKlebsiella pneumoniaeDrug CombinationsAzabicyclo CompoundsMeropenemKlebsiella InfectionsAnti-Bacterial AgentsDrug SynergismDisease Models, Animalbeta-LactamasesMicrobial Sensitivity TestsBacterial ProteinsAnimalsMiceFemaleWhole Genome SequencingDrug Therapy, CombinationCarbapenem-Resistant Enterobacteriaceae

Substanzen

CeftazidimeDrug CombinationsAzabicyclo Compoundsavibactam, ceftazidime drug combinationMeropenemAnti-Bacterial Agentsbeta-LactamasescarbapenemaseBacterial Proteins

Autor:innen und Institutionen

  • State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China.
  • Guangdong Laboratory for Lingnan Modern Agriculture, National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Gua…
  • Service of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, 1211, Switzerland.
  • Infectious Diseases Division, Federal University of Sao Paulo-UNIFESP, Escola Paulista de Medicina, São Paulo, Brazil.
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.

ORCID-Profile: Ana C Gales, Wan-Jiang Zhang, Jian Sun

Förderung

  • Swiss National Science Foundation
  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Geneva University Hospitals

Zitieren

APA

Zheng, M., Li, F. H., Liu, J., Li, W. J., Yin, R. X., Cai, D. T., Andrey, D. O., Zheng, S. L., Gales, A. C., Zhang, W. J., Sun, J., Liao, X. P., & Yu, Y. (2024). Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae074

Vancouver

Zheng M, Li FH, Liu J, Li WJ, Yin RX, Cai DT, et al. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae074

BibTeX
@article{Zheng2024,
  author = {Zheng, Mei and Li, Fu-Hao and Liu, Juan and Li, Wen-Jie and Yin, Ruo-Xi and Cai, Da-Tong and Andrey, Diego O and Zheng, Si-Lin and Gales, Ana C and Zhang, Wan-Jiang and Sun, Jian and Liao, Xiao-Ping and Yu, Yang},
  title = {Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae074}
}
Kostenlos starten →